Sep 14, 2022 / 02:35PM GMT
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity Analyst
Great. Thanks, everyone, for joining another session at the conference. I'm Drew Ranieri, one of the medical device analysts here. And it's my absolute pleasure to have Baxter International with us today, CFO, Jay Saccaro; and VP of Investor Relations, Clare Trachtman.
Before we go into Q&A, just to highlight the disclosure, but for important disclosures, please see the Morgan Stanley research disclosure website. And if you have any questions, reach out to your Morgan Stanley sales rep.
Questions and Answers:
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity AnalystSo Jay, on to Q&A, and thank you again for being here. And kind of with the rumor that came out last night about potential asset sales, I know you won't necessarily comment on it specifically, but I mean, there has been a lot happening in the renal space from the corporate action side in 2022 on top of some government regulatory positive changes in targeting, moving care into